Proscia's platform, Concentriq, processes over 12 million pathology cases annually across more than 4,000 hospitals and clinics worldwide, with adoption by 16 of the top 20 pharmaceutical companies. The AI-native digital pathology platform supports workflows from cancer discovery through diagnosis and treatment understanding. The attack surface here is significant: medical image data at scale, AI model integrity, and integration points across healthcare and pharmaceutical environments where the stakes are patient outcomes.
The threat model for a system like Concentriq involves protecting sensitive medical imaging data, ensuring the integrity of AI-powered diagnostic intelligence, and securing integrations across a distributed network of clinical and research institutions. Security work at Proscia operates at the intersection of healthcare compliance requirements, precision medicine data pipelines, and production AI systems - domains where a compromised model or a data exposure isn't just a breach statistic but a direct risk to patient care.
Founded in 2014, Proscia's technical domains span AI, healthcare, precision medicine, and digital pathology. The company states its team thrives on solving problems at the intersection of these fields, where the company notes every line of code and every model has the potential to impact patient outcomes. The global footprint and scale of deployment mean security engineering here involves real-world clinical infrastructure, not sandboxed prototypes.
